Sign up Australia
Proactive Investors - Run By Investors For Investors

Pharmaxis' CEO Gary Phillips updates on partnership with Boehringer Ingelheim

Pharmaxis will receive €10 million milestone payment when the first patient is dosed in this 2nd indication Phase IIa study.

 
Meet Great Boulder Resources Ltd, Mainstream Group Holdings Ltd, Blackstone Minerals Ltd, Pacific American Coal Ltd and Reward Minerals Ltd at our event, Sydney , 19 November 2018. Register here »
View full PXS profile View Profile

Pharmaxis Ltd Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use